Glucovance is a fixed-dose combination of metformin hydrochloride and glibenclamide, paired in a single oral preparation for the management of type 2 diabetes mellitus. Combination products of this kind formalise a pairing that clinicians often arrive at separately — a biguanide-style background therapy alongside a sulfonylurea-style insulin-secretion agent — by placing both into one tablet, which can simplify a daily regimen for patients already established on the two ingredients.
The two active ingredients sit in distinct pharmacological categories. Metformin is one of the long-standing backbone agents in the broader class of drugs used in diabetes, while glibenclamide (also spelled glyburide in some markets) is a hypoglycaemic agent that acts through a different route. Combining them in one product is intended to address blood-glucose control through complementary mechanisms rather than a single pathway.
Glucovance is registered in 36 countries, with a footprint that spans Latin America, parts of Europe, the Middle East, North Africa, and Southeast Asia. Representative markets include Brazil, France, Egypt, Malaysia, and Australia. The structured data block further down this page lists the full set of countries and the registered indications recognised by their national regulators.
Combination diabetes products vary across countries even more than single-ingredient ones, both in the precise ratios used and in which sulfonylurea is paired with metformin in a given market. A local pharmacist can confirm whether Glucovance or a comparable fixed-dose product is available, and any decision to start, stop, or switch a diabetes regimen should sit with the healthcare provider managing the patient's overall care.
